Health News

U.K.'s NICE Issues Final Appraisal Determination Recommending Alimera's ILUVIEN® for Chronic Diabetic Macular Edema

Author: Australian Business

ATLANTA, Sept. 30, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that in its Final Appraisal......

More...

More Articles...

Halaven® (Eribulin), innovatives Medikament für die Behandlung von metastasiertem Brustkrebs nun in Belgien erhältlich
Halaven® (éribuline), traitement innovant pour le cancer du sein desormais disponible en Belgique
2013 CareFlite Paluxy Pedal Promotes Health And Education
REVISED: Triple-S Management Corporation Announces Departure of Susan Rawlings-Molina; Names Carlos A. Carrero as Successor
Alan Alda And Joe Mantegna To Host HOMEWARD BOUND: A Telethon Supporting Veterans With PTSD TBI
Rogers Memorial Hospital Hosts Interactive Video Chat on OCD Treatment
Coverall Franchise Owner Damion Jones Recognized For Outstanding Contributions To Franchising
Fattah Introduces House Resolution Recognizing World Alzheimer's Month
First National Conference on Mental Health Issues of Diabetes
Leading Pharma Company Selects Clinilabs to Conduct a Phase 1 Study of an Investigational Type 2 Diabetes Medication

Page 1314 of 1908

U.K.'s NICE Issues Final Appraisal Determination Recommending Alimera's ILUVIEN&reg; for Chronic Diabetic Macular Edema

More Articles...

U.K.'s NICE Issues Final Appraisal Determination Recommending Alimera's ILUVIEN® for Chronic Diabetic Macular Edema